These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31896526)

  • 1. Functional Cellular Anti-Tumor Mechanisms are Augmented by Genetic Proteoglycan Targeting.
    Gupta P; Johns SC; Kim SY; El Ghazal R; Zuniga EI; Fuster MM
    Neoplasia; 2020 Feb; 22(2):86-97. PubMed ID: 31896526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia.
    Kim SY; Johns SC; Gupta P; Varki N; Fuster MM
    Neoplasia; 2021 Nov; 23(11):1137-1143. PubMed ID: 34715561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alteration of heparan sulfate in CD11c + immune cells inhibits inflammation and facilitates pathogen clearance during influenza A virus infection.
    Kim SY; Gupta P; Johns SC; Zuniga EI; Teijaro JR; Fuster MM
    Sci Rep; 2022 Mar; 12(1):5382. PubMed ID: 35354833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycan Sulfation Modulates Dendritic Cell Biology and Tumor Growth.
    El Ghazal R; Yin X; Johns SC; Swanson L; Macal M; Ghosh P; Zuniga EI; Fuster MM
    Neoplasia; 2016 May; 18(5):294-306. PubMed ID: 27237321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferon activates MHC class I-dressed CD11b
    Duong E; Fessenden TB; Lutz E; Dinter T; Yim L; Blatt S; Bhutkar A; Wittrup KD; Spranger S
    Immunity; 2022 Feb; 55(2):308-323.e9. PubMed ID: 34800368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.
    Knittel D; Gadzinski A; Hua S; Denizeau J; Savatier A; de la Rochère P; Boulain JC; Amigorena S; Piaggio E; Sedlik C; Léonetti M
    Vaccine; 2016 Jun; 34(27):3093-3101. PubMed ID: 27154391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
    Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
    J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct CD4 help provision following interaction of memory CD4 and CD8 T cells with distinct antigen-presenting dendritic cells.
    de Goër de Herve MG; Dembele B; Vallée M; Herr F; Cariou A; Taoufik Y
    J Immunol; 2010 Jul; 185(2):1028-36. PubMed ID: 20562265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation.
    Steinman RM
    Mt Sinai J Med; 2001 May; 68(3):160-6. PubMed ID: 11373688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.
    Li S; Simoni Y; Zhuang S; Gabel A; Ma S; Chee J; Islas L; Cessna A; Creaney J; Bradley RK; Redwood A; Robinson BW; Newell EW
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34285073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
    Tian H; Shi G; Yang G; Zhang J; Li Y; Du T; Wang J; Xu F; Cheng L; Zhang X; Dai L; Chen X; Zhang S; Yang Y; Yu D; Wei Y; Deng H
    BMC Cancer; 2014 Jan; 14():48. PubMed ID: 24475975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.
    Keller AM; Xiao Y; Peperzak V; Naik SH; Borst J
    Blood; 2009 May; 113(21):5167-75. PubMed ID: 19279334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.